PCRX
Pacira BioSciences, Inc.
Overview
Pacira BioSciences provides non-opioid pain management therapies for surgical and osteoarthritis patients. The company markets three commercialized products: EXPAREL (long-acting local anesthetic for postsurgical pain), ZILRETTA (extended-release corticosteroid injection for knee osteoarthritis), and iovera° (cryoanalgesia device for nerve pain relief).
Pacira BioSciences, Inc is a Healthcare company operating in Drug Manufacturers - Specialty & Generic with a $893.6M market cap.
Most recent reported earnings: Q2 FY2026 (Aug 3, 2026).
21 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from Unknown source, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q1 FY2026Earnings2026-04-309 Q&A exchanges
- Q4 FY2025Earnings2026-02-2611 Q&A exchanges
- Q3 FY2025Earnings2025-11-079 Q&A exchanges
- Q2 FY2025Earnings2025-08-069 Q&A exchanges
- Q1 FY2025Earnings2025-05-0815 Q&A exchanges
- Q4 FY2024Earnings2025-02-2715 Q&A exchanges
- Q3 FY2024Earnings2024-11-068 Q&A exchanges
- Q2 FY2024Earnings2024-07-3016 Q&A exchanges
- Q1 FY2024Earnings2024-05-0717 Q&A exchanges
- Q4 FY2023Earnings2024-02-2911 Q&A exchanges
- Q3 FY2023Earnings2023-11-0213 Q&A exchanges
- Q2 FY2023Earnings2023-08-0217 Q&A exchanges
- Q1 FY2023Earnings2023-05-038 Q&A exchanges
- Q4 FY2022Earnings2023-02-2812 Q&A exchanges
- Q3 FY2022Earnings2022-11-0310 Q&A exchanges
- Q2 FY2022Earnings2022-08-039 Q&A exchanges
- Q1 FY2022Earnings2022-05-0417 Q&A exchanges
- Q4 FY2021Earnings2022-02-2427 Q&A exchanges
- Q3 FY2021Earnings2021-11-0327 Q&A exchanges
- Q2 FY2021Earnings2021-08-0422 Q&A exchanges
- Q1 FY2021Earnings2021-05-1229 Q&A exchanges
History
Earnings history
- Q2 FY20262026-08-03EPS— vs $0.27—Rev— vs ——EODHD
- Q1 FY20262026-05-06EPS$0.60 vs $0.76-20.7%Rev$177.4M vs ——EODHD
- Q4 FY20252026-02-18EPS$0.57 vs $0.90-36.8%Rev$196.9M vs ——EODHD
- Q3 FY20252025-11-05EPS$0.70 vs $0.65+7.7%Rev$179.5M vs ——EODHD
- Q2 FY20252025-08-04EPS$-0.11 vs $0.72-100.0%Rev$181.1M vs ——EODHD
- Q1 FY20252025-05-04EPS$0.62 vs $0.60+3.8%Rev$168.9M vs ——EODHD
- Q4 FY20242025-02-25EPS$0.91 vs $0.83+9.6%Rev$187.3M vs ——EODHD
- Q3 FY20242024-11-05EPS$0.79 vs $0.70+12.9%Rev$168.6M vs ——EODHD
- Q2 FY20242024-07-29EPS$0.89 vs $0.70+27.1%Rev$178.0M vs ——EODHD
- Q1 FY20242024-05-06EPS$0.62 vs $0.620.0%Rev$167.1M vs ——EODHD
- Q4 FY20232024-02-28EPS$0.89 vs $0.88+1.1%Rev$181.2M vs ——EODHD
- Q3 FY20232023-11-01EPS$0.72 vs $0.78-7.7%Rev$163.9M vs ——EODHD
- Q2 FY20232023-08-01EPS$0.78 vs $0.76+2.6%Rev$169.5M vs ——EODHD
- Q1 FY20232023-05-02EPS$0.53 vs $0.62-14.5%Rev$160.3M vs ——EODHD
- Q4 FY20222023-02-27EPS$0.80 vs $0.83-3.6%Rev$172.0M vs ——EODHD
- Q3 FY20222022-11-02EPS$0.64 vs $0.76-15.8%Rev$167.5M vs ——EODHD
- Q2 FY20222022-08-02EPS$0.51 vs $0.85-40.0%Rev$169.4M vs ——EODHD
- Q1 FY20222022-05-03EPS$0.64 vs $0.83-22.9%Rev$158.0M vs ——EODHD
- Q4 FY20212022-02-23EPS$0.97 vs $0.90+7.8%Rev$159.2M vs ——EODHD
- Q3 FY20212021-11-02EPS$0.72 vs $0.65+10.8%Rev$127.7M vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-03 | — | $0.27 | — | — | — | — | EODHD |
| Q1 FY2026 | 2026-05-06 | $0.60 | $0.76 | -20.7% | $177.4M | — | — | EODHD |
| Q4 FY2025 | 2026-02-18 | $0.57 | $0.90 | -36.8% | $196.9M | — | — | EODHD |
| Q3 FY2025 | 2025-11-05 | $0.70 | $0.65 | +7.7% | $179.5M | — | — | EODHD |
| Q2 FY2025 | 2025-08-04 | $-0.11 | $0.72 | -100.0% | $181.1M | — | — | EODHD |
| Q1 FY2025 | 2025-05-04 | $0.62 | $0.60 | +3.8% | $168.9M | — | — | EODHD |
| Q4 FY2024 | 2025-02-25 | $0.91 | $0.83 | +9.6% | $187.3M | — | — | EODHD |
| Q3 FY2024 | 2024-11-05 | $0.79 | $0.70 | +12.9% | $168.6M | — | — | EODHD |
| Q2 FY2024 | 2024-07-29 | $0.89 | $0.70 | +27.1% | $178.0M | — | — | EODHD |
| Q1 FY2024 | 2024-05-06 | $0.62 | $0.62 | 0.0% | $167.1M | — | — | EODHD |
| Q4 FY2023 | 2024-02-28 | $0.89 | $0.88 | +1.1% | $181.2M | — | — | EODHD |
| Q3 FY2023 | 2023-11-01 | $0.72 | $0.78 | -7.7% | $163.9M | — | — | EODHD |
| Q2 FY2023 | 2023-08-01 | $0.78 | $0.76 | +2.6% | $169.5M | — | — | EODHD |
| Q1 FY2023 | 2023-05-02 | $0.53 | $0.62 | -14.5% | $160.3M | — | — | EODHD |
| Q4 FY2022 | 2023-02-27 | $0.80 | $0.83 | -3.6% | $172.0M | — | — | EODHD |
| Q3 FY2022 | 2022-11-02 | $0.64 | $0.76 | -15.8% | $167.5M | — | — | EODHD |
| Q2 FY2022 | 2022-08-02 | $0.51 | $0.85 | -40.0% | $169.4M | — | — | EODHD |
| Q1 FY2022 | 2022-05-03 | $0.64 | $0.83 | -22.9% | $158.0M | — | — | EODHD |
| Q4 FY2021 | 2022-02-23 | $0.97 | $0.90 | +7.8% | $159.2M | — | — | EODHD |
| Q3 FY2021 | 2021-11-02 | $0.72 | $0.65 | +10.8% | $127.7M | — | — | EODHD |
Source: EODHD. PCRX reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks PCRX's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters but stock falls 100% of the time
SampleWhen a company consistently beats but the stock doesn't react, consensus is usually set too low or the buy-side number is materially above sell-side. Watch for guidance walk-downs ahead of the print.
Raised guidance 3 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $4.50 | $3.95 | +14.0% | -2.9% | -0.2% |
| Q4 FY2026 | $4.46 | $4.10 | +8.9% | -8.8% | -11.2% |
| Q3 FY2026 | $4.70 | $4.14 | +13.5% | -7.1% | -5.6% |
| Q2 FY2026 | $4.25 | $4.18 | +1.7% | -5.3% | -5.7% |
| Q1 FY2025 | $4.25 | $4.20 | +1.1% | -0.3% | +0.2% |
| Q4 FY2025 | $4.22 | $4.04 | +4.4% | -0.4% | -1.6% |
| Q3 FY2025 | $4.42 | $4.00 | +10.6% | -5.3% | -4.3% |
| Q2 FY2025 | $4.75 | $4.20 | +13.0% | -3.4% | -0.7% |
| Q1 FY2024 | $4.32 | $4.23 | +2.2% | -3.9% | -4.5% |
| Q4 FY2024 | $4.54 | $4.06 | +11.7% | -5.8% | -6.1% |
Guidance change history
Sample- Q1 FY2026Raised2026-04-15
- Q4 FY2026Raised2026-13-15
- Q3 FY2026Raised2026-10-15
- Q2 FY2026Maintained2026-07-15
- Q1 FY2025Maintained2025-04-15
- Q4 FY2025Raised2025-13-15
- Q3 FY2025Raised2025-10-15
- Q2 FY2025Raised2025-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Frank D LeeCEO5 mo10 callsCurrentSample
CEO since 2026 • 1/2 beats (50%) • guidance suspended Q3 FY2026
- Shawn CrossCFO8 mo7 callsCurrentSample
CFO since 2025 • 3/4 beats (75%) • last guidance cut Q2 FY2026
- Brendan TeehanChief Commercial Officer6 mo5 callsCurrentSample
OTHER_C_SUITE since 2025 • 3/4 beats (75%) • last call held guidance Q3 FY2026
- Jonathan SloninChief Medical Officer1 yr6 callsCurrentSample
OTHER_C_SUITE since 2025 • 2/4 beats (50%) • last guidance cut Q2 FY2026
- Kristen WilliamsChief Administrative Officer1 yr1 callCurrentSample
OTHER_C_SUITE since 2025 • 2/4 beats (50%) • last guidance raise Q2 FY2026
- Lauren RikerSenior Vice President, Finance1 yr1 callCurrentSample
OTHER since 2025 • 2/4 beats (50%) • last call held guidance Q1 FY2026
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for PCRX.
$ curl https://api.spokenalpha.com/v1/companies/PCRXFAQ
Frequently asked about PCRX
Where can I find Pacira BioSciences, Inc.'s (PCRX) earnings call transcripts?
Spoken Alpha indexes PCRX's earnings call transcripts at https://spokenalpha.com/companies/PCRX. Each call links to attributed speakers and parsed analyst Q&A. Pacira BioSciences, Inc.'s own investor relations page is at https://investor.pacira.com/.
When was Pacira BioSciences, Inc.'s most recent earnings call?
Pacira BioSciences, Inc. (PCRX) held its most recent earnings call on 2026-04-30, covering fiscal Q1 2026.
What sector is PCRX in?
Pacira BioSciences, Inc. (PCRX) operates in the Healthcare sector (Drug Manufacturers - Specialty & Generic industry).